Updates
Jubilant receives ANDA approval for Amlodipine and Olmesartan Medoxomil Tablets17-05-2017
Board to consider FY17 Results & Dividend on May 23, 2017
Jubilant Life Sciences Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on May 23, 2017, inter alia, to consider:1. Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2017;2. Recommendation of Dividend for the Financial Year ended March 31, 2017.11-05-2017
Updates
Schedule of Investor Conference Call for Jubilant Life Sciences Limited - Audited Financial Results for the year ended March 31, 201711-05-2017
Intimation Of Board Meeting May 23, 2017
In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, May 23, 2017, to inter-alia consider: 1.Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2017; 2.Recommendation...11-05-2017
Updates
Disclosure under Regulation 30(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended09-05-2017
Jubilant Life to buy Triad Isotopes' radio-pharmacy biz
Jubilant Life Sciences' subsidiary Jubilant Pharma will acquire the radio-pharmacy business of US-based Triad Isotopes for an undisclosed sum. Jubilant Pharma Ltd (JPL)... through one of its...05-05-2017
Updates
Submission of copies of newspaper advertisements for Transfer of Equity Shares to Investor Education and Protection Fund03-05-2017